Simcere is a pharmaceutical company with innovation and R&D as its core driving force, and is committed to "making patients use more effective drugs as soon as possible". It has three R&D centers in Nanjing, Shanghai and Boston, and has been approved by the Ministry of Science and Technology to establish the State Key Laboratory of Translational Medicine and Innovative Drugs. It has been ranked among the "Top Ten Innovative Pharmaceutical Enterprises in China" and "Top 100 Pharmaceutical Industries in China" for many years.
Simcere focuses on "tumor (including cell therapy), central nervous system and autoimmunity" and has a diversified and innovative product portfolio. Xiansheng Technology adheres to the open and innovative R&D strategy, establishes strategic cooperation with domestic and foreign pharmaceutical companies and biotechnology companies, and promotes the value realization of global life science achievements in China.
R&D:
By the end of June 2020, 65438+February 3 1, there were more than 60 R&D pipelines, including more than 50 innovative drug R&D pipelines. It has the pharmaceutical capacity of integrating macromolecular and micromolecule raw materials and preparations, among which more than 0/0 innovative drug products under research are in the clinical stage and have been submitted for new drug declaration or approval.
In addition to the above-mentioned products under research, there are more than 30 innovative drugs under research in three major fields.